Antimicrobial peptides (AMPs) are compounds that act in a wide range of physiological defensive mechanisms developed to counteract bacteria, fungi, parasites and viruses. These molecules have become increasingly important as a consequence of remarkable microorganism resistance to common antibiotics. This report shows Escherichia coli expressing the recombinant antimicrobial peptide Pg-AMP1 previously isolated from Psidium guajava seeds. The deduced Pg-AMP1 open reading frame consists in a 168 bp long plus methionine also containing a His6 tag, encoding a predicted 62 amino acid residue peptide with related molecular mass calculated to be 6.98 kDa as a monomer and 13.96 kDa at the dimer form. The recombinant Pg-AMP1 peptide showed inhibitory activity against multiple Gram-negative (E. coli, Klebsiella pneumonia and Pseudomonas aeruginosa) and Gram-positive (Staphylococcus aureus and Staphylococcus epidermides) bacteria. Moreover, theoretical structure analyses were performed in order to understand the functional differences between natural and recombinant Pg-AMP1 forms. Data here reported suggest that Pg-AMP1 is a promising peptide to be used as a biotechnological tool for control of human infectious diseases.
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Introduction
In recent years, the number of bacteria with enhanced resistance to conventional antibiotics has dramatically increased [10] .
Abbreviations: AMPs, antimicrobial peptides; ATCC, American type culture collection; BL21-(DE3), bacterial expression systems; BSA, bovine serum albumin; CFU, colony-forming unit; GRPs, glycine rich proteins; GST, glutathione S-transferase; HDP, host-defense peptide; DOPE, discrete optimized protein energy; His6, hexa histidine tag; IMAC, immobilized metal affinity chromatography; IPTG, isopropyl ␤-d-1-thiogalacto pyronoside; LAMP-1a, Leymus arenarius antimicrobial peptide 1a; LB, Luria-Bertani broth medium; LOMETS, local meta-threading-server; MBP, maltose binding protein; MIC, minimal inhibitory concentration; NusA, N-utilizing substance A protein; pBSK, expression and cloning plasmid; Pg-AMP1, Psidium guajava antimicrobial peptide 1; PR-39, proline-rich antibacterial peptide; PrDOS, protein DisOrder prediction system; ProSA, protein structure analysis; PT7, bacteriophage promoter; RBCs, human red blood cells; Trx, thioredoxin A.
Many hospital infections have been difficult to treat due to opportunistic bacterial infections. Many of these bacteria belong to regular microbial flora, making them a real challenge for immune-depressed patients. In general, treatment is expensive and inefficient, encouraging several research groups to screen novel antimicrobial compounds [9, 40] . Among them, antimicrobial peptides (AMPs) have been focused since they are the first natural barrier against microorganisms from almost all living groups [40] .
AMPs are constitutively expressed or induced by endogenous or exogenous elicitors, such as developmental stage or pathogen predation [32] . AMPs are small proteins, 20-50 amino acid residues long, and in some organisms constitute the primary innate host defense line, often have common properties such as the small number of amino acid residues, cationicity and amphipathicity [25] . Although various AMPs have been isolated in different kingdoms, several structural scaffolds are quite common and may be related to a single promiscuous class of peptides with multiple functions [8] . The mechanism of action include select electrostatic interactions that may induce lipid bilayer depolarization, permeability alterations and ion imbalance [28] that may lead to membrane disruption. Moreover, the presence of AMPs could also lead to alteration of several gene expressions, improving protein synthesis and modifying enzyme activities [32] . In the last two decades a number of studies have shown that AMPs act synergistically to the immune response [10, 23] , making isolation, identification and characterization of natural AMPs an important tool for development of a new generation of drugs [11, 23, 39] .
Among the AMPs, the glycine-rich proteins (GRPs) are a group of proteins that occurs in a wide variety of organisms. This group carries glycine-rich repeat domains [2, 24] and their expressions in plants are normally modulated by abiotic and biotic stresses, showing defensive activity against fungi, bacteria and viruses [2] . Pelegrini et al. [28] demonstrated that a GRP isolated from guava seeds, denominated Pg-AMP1, showed activity against human pathogenic Gram-negative bacteria such as Escherichia coli, Klebsiella sp. and Proteus sp. In spite of the clear bactericidal activity observed, purification and yield of Pg-AMP1 was extremely low, reaching approximately 1 mg of peptide from almost 10 kg of total guava seeds [28] . This protein quantity was insufficient to allow novel experiments or to use these peptides as a biotechnological tool for infectious disease treatment. Furthermore, Pg-AMP1chemical synthesis, a peptide 55 amino acid residues long, is extremely expensive, therefore for Pg-AMP1 the strategy of recombinant protein production in a heterologous system is essential. However, few articles described heterologous expression of recombinant glycine-rich antimicrobial peptides. Feng et al. [7] expressed SK66-His and Sperstad et al. [37] expressed the GRP-denominated hystatin, that showed deleterious activity against Gram-positive and Gram-negative bacteria and yeasts. Furthermore, Shlyapnikov et al. [36] cloned and expressed a synthetic gene in a pET vector. This gene, named Ltc2a (latarcin 2a), was fused to 6 glycine residues and further demonstrated protective activity against E. coli and Bacillus subtilis.
The number of recombinant antimicrobial peptides expressed has greatly increased in recent years due to advances in molecular biology, allowing the establishment of strategies for expression such as host choice, promoter type and appropriate post-transcriptional modification features [33] . Bacterial systems remain highly attractive due to low cost, high productivity and rapid use. Although the bacterial systems seems to be useful for eukaryotic protein expression some limitations must be overcome, such as codon usage, incorrect folding, protein degradation by protease from host cell and host toxicity caused by heterologous protein [14] . Over-expression of heterologous proteins in E. coli often produces high quantities of insoluble protein. In order to overcome such limitations, the optimization of expression conditions such as temperature, growth media, induction parameters, promoters and E. coli expression strain maybe used [33] . Fusion tags as Trx, NusA, GST, MBP and His6 were able to increase protein solubility, improving the purification processes by decreasing production costs and increasing yield [27, 31] . Although fusion tags maybe interesting since they facilitate peptide solubility and purification, these tags can also often interfere within protein structure and/or function. Consequently, it is commonly recommended that the tag be removed after the purification process [27] , although Carson et al. [3] have shown that the His6 tag does not normally alter the structure of recombinant proteins. Tag removal can be performed by proteolytic cleavage, but this approach can be problematic due to non-specific and inefficient cleavage or loss of protein stability and solubility [27] . Another factor that impairs heterologous antimicrobial peptide expression in E. coli is cytotoxic AMP activity against the bacterial host. This leads to clear difficulties in scale-up and to low yields processing requires chemicals or expensive enzymes, and multistep purification of peptides reduces yield, thus making peptide production less cost effective [1] . In spite of all these problems, some studies describe the expression of AMPs in prokaryotic expression system as E. coli with yielding varying from 2 mg L −1 to 40 mg L −1 [18, 19, 33, 38, 41] .
In the present work the guava GRP gene, named Pg-AMP1, was synthesized and further expression strategy was designed for production of the recombinant peptide in a prokaryotic system. Recombinant Pg-AMP1 was further evaluated for biological activity against human pathogenic bacteria. Moreover, theoretically structural studies comparing the native and recombinant Pg-AMP1 forms were also carried out to shed some light on structure-function relationship. 
Materials and methods

Bacterial strains
Gram-negative bacteria
Gene synthesis and vector construction
The gene encoding Pg-AMP1, 168 bp long, was designed to be expressed carrying a His6 tag fused to C-terminal. The codon was optimized for E. coli expression and the cassette expression was synthesized by Epoch Biolabs and cloned into SmaI site of pBluescriptIISK(−). The expression cassette is composed of Pg-AMP1 gene under control of T7/lac promoter/terminator plus met codon His6 tag encoding a peptide with 62 amino acid residues ( Fig. 1 ).
Expression of recombinant Pg-AMP1
Recombinant plasmid pBSKPg-AMP1 was used for transformation of E. coli BL21 (DE3) electrocompetent cells (Invitrogen, Carlsbad, CA). The induction was done according to the instruction manual His Trap FF crude (GE, Upsala), using IPTG as an inducer and ampicillin (100 g mL −1 ) as select agent. The IPTG induction (0, 0.5 and 1 mM) was done during 2, 4 or 6 h. Soluble and insoluble fractions were evaluated in each treatment.
Isolation of recombinant peptide
BL21 (DE3) cells were grown for 4 h from 500 mL of LB at 300 rpm. Pellet cells were obtained from 4500 × g at 4 • C after 15 min centrifugation. Pellets were resuspended in lysis buffer (1:10 v/v) containing 50 mM sodium phosphate (pH 7.8), 300 mM sodium chloride, 50 mM potassium chloride, 10% glycerol, 0.5% Triton X-100 and 10 mM imidazole. Enzymatic lysis was performed for 30 min at room temperature with 0.2 mg mL −1 lysozyme, 20 g mL −1 DNAse, 1 mM MgCl and 1 mM phenylmethylsulfonylfluoride. Mechanical lysis was carried out by sonication on ice for approximately 10 min (in several short bursts). Suspension cells were disrupted by sonication (Sonics -Vibra Cell) 20 kHz 100% using the v188 probe on ice four times for 20 s separated by 1 min elapsed time. The suspension was centrifuged at 4500 × g at 4 • C for 30 min. Supernatant carrying soluble proteins were stored −20 • C for subsequent analysis. For each gram of pellet, 3 mL of lysis buffer containing 300 mM sodium chloride, 50 mM sodium phosphate (pH cgcgaaattaatacga ctcactataggg gaattgtgagcg gataacaattcc cctctaga aataattttgtttaac tttaagaaggag atatacatatgc gtgagtctccga gtagccgc M R E S P S S R atggaatgctatgaac aggcggagcgtt atgggtacggcg gctatggtggcg gtcgttac 7.4), 10 mM ␤-mercaptoethanol and 10 g mL −1 protease cocktail inhibitor (SIGMA) was added in order to resuspend insoluble fraction. The suspension was kept at room temperature for 30 min and sonicated again for 3× 20 s separated by 1 min interval on ice. The suspension was centrifuged at 4500 × g at 4 • C for 15 min. The pellet was treated with two different buffers (A and B) for suspension of insoluble aggregates. Buffer A (6 M Gua-HCl, 300 mM sodium chloride, 50 mM sodium phosphate (pH 7.4) and 20 mM imidazole) and buffer B (8 M urea, 300 mM sodium chloride and 20 mM imidazole) in order to identify the fraction soluble or insoluble in which the peptide is located. The suspensions containing soluble peptides were centrifuged at 4500 × g at 4 • C for 15 min and the pellet was resuspended in100 L of distilled water. Protein purification was performed by immobilized metal ion affinity chromatography (IMAC) in a Nickel His-Trap 1 mL column (GE, Upsala) using imidazole in binding buffer (20 mM imidazole) and eluted with imidazole elution buffer (500 mM Imidazole). The clarified lysate was placed in affinity column Crude His Trap FF crude columns 1 mL (GE) for purification according to the manufacturer's instructions.
Tricine-SDS-PAGE analyses
Protein samples were electrophoresed in Tricine-SDS-PAGE (16%) under non-denaturating conditions as described by Schagger [34] with minor modifications. Protein quantification was carried out according to Lowry [22] and BSA (bovine serum albumin) was used as the standard. The Pg-AMP1 (50 g) was mixed with sample buffer Electrophoresis was performed in the Mini-PROTEAN Tetra Electrophoresis System ® (Bio-Rad). Peptides were fixed and further silver stained. Ultra low range molecular weight marker (1.6-26.6 kDa) from Sigma TM and protein marker (2-212 kDa) (New England Biolabs, Ipswich, MA) was used as standard.
Western blotting
Tris-Tricine-SDS-PAGE gel was electro-blotted for 20 min at 100 V onto an RPN3032D (0.20 m pore size) nitrocellulose membrane (Amersham Hybond-ECL/GE). Membrane was washed in PBS and blocked by immersing the membrane in PBS-T 0.1%. The membrane was primarily incubated with anti-His antibody (GE) (1:1000) overnight then washed in PBS-T and incubated with the secondary antibody (1:1000) diluted in PBS with 3% antibody anti-mouse IgG peroxidase conjugate (GE) added for 1 h at room temperature detection was carried out in a dark room using Amersham ECL Prime Western Blotting Detection Reagent (GE) on auto radiography film (Amersham Hyperfilm ECL).
Antibacterial assays
Antimicrobial activities of recombinant purified Pg-AMP1 were tested against the after mentioned Gram-negative and Gram-positive bacteria. Polypropylene microplates were used to inoculate 100 L of TSB medium containing the microorganism (concentration of 5 × 10 4 CFU mL −1 well −1 ) and 100 L of Pg-AMP1 recombinant peptide dissolved in saline solution (0.9 g L −1 ) at different concentrations (25, 50 and 100 g mL −1 ) to determine the minimal inhibitory concentration (MIC). Two sets of negative control were used: (I) bacteria treated with wash buffer 20 mM sodium phosphate, 500 mM imidazole, sodium 0.5 M chloride (pH 7.4); (II) saline solution (0.9 g L −1 ). Chloramphenicol was used as positive control at 1000, 100, 50 and 25 g mL −1 dissolved in saline solution (0.9 g L −1 ). Each treatment was performed in triplicate according to NCCLS [26] . The cell growth was monitored by turbidimetry absorbance at 600 nm using the Elisa Espectra Max 190 (Molecular Devices). In order to determine the bactericidal or bacteriostatic action of Pg-AMP1, 20 L of each treatment was reinoculated in 1 mL of liquid TSB and incubated for 16 h at 37 • C under 100 rpm and the cell growth was measured by turbidimetry absorbance at 600 nm using the Elisa Espectra Max 190 (Molecular Devices).
Hemolysis assays
Hemolytic activity assays were performed as described by Jang et al. [15] . Three mL of fresh human red blood cells (RBCs) was washed with 9 mL of sterile isotonic phosphate-buffered saline, pH 7.4 (PBS), until the color of the supernatant turned clear. The washed RBCs were then diluted to final volume of 20 mL with the PBS buffer and 10 L of different solutions of Pg-AMP1 PBS diluted (200, 100 and 50 g mL −1 ) was added to 190 L of the cell suspension in 0.5 mL microfuge tubes. Following the gentle mixing, the tubes were incubated at 37 • C for 30 min and then centrifuged at 4000 × g for 5 min. One hundred microliter of supernatant was taken, diluted to 1 mL with PBS, and 100 L were removed and placed in a microplate to be read in Varioskan (Thermo) under 567 nm absorbance and the released hemoglobin indicated RBC membrane damage. Zero hemolysis and 100% hemolysis consisted of RBC suspended in PBS and 0.2% Triton X-100, respectively. The percentage of hemolysis was determined as follows:
A s corresponds to the absorbance of the treatment, A 100 corresponds to the absorbance of completely lysed RBC in 0.2% Triton X-100, and A 0 corresponds to the absorbance of zero hemolysis in PBS. The highest concentration of peptide that did not induce hemolysis was defined as the 'minimum hemolytic concentration' (MHC).
Molecular modeling
Sequences of Pg-AMP1 and its recombinant form were submitted to Local Meta-Threading-Server (LOMETS) [43] . However, no significant templates were found. Therefore, Monte-Carlo simulations were performed by QUARK Ab initio server [45] in order to create an initial structure. Based on this initial structure, Modeller 9.9 [6] was used to generate 100 novel structures through loop-refinement sub-routine and structural information from PsiPred [13] and Protein DisOrder prediction System (PrDOS) [25] . Ten models with minor discrete optimized protein energy (DOPE score) for each sequence were selected and analyzed on PROCHECK [20] and protein structure analysis (ProSA) [42] . Models were visualized on PyMOL (The PyMOL Molecular Graphics System, Version 1.4.1, Schrödinger, LLC).
Results
Expression of recombinant peptide
The expression of recombinant Pg-AMP1 peptide in BL21 (DE3) after purification yielded 2 mg L −1 and the highest expression level was obtained after 4 h induction with 0.5 mM IPTG (data not shown). The Pg-AMP1 was fused to a histidine tag producing a 6.983 kDa peptide that showed a predicted pI of 8.01(http://expasy.org/cgi-bin/pi tool). Thus, heterologous expression of peptide in E. coli strain BL21-(DE3) carrying the plasmid pBSKPg-AMP1 with His6 tag was demonstrated. Peptide was found in the soluble fraction, thus facilitating the later stages of purification.
Isolation of recombinant peptide
The Pg-AMP1 was first fused to a histidine tag aiming to facilitate purification. Soluble fraction of non-clarified cell lysate was direct loaded to IMAC (GE Crude His Trap FF) and western blot analysis confirmed the presence of isolated peptide Pg-AMP1with a molecular mass of approximately 14 kDa due dimer formation in non-denaturating gel (Fig. 2) . Release hemoglobin into supernatant was monitored in order to indicate the RBC membrane damage. PBS was used as negative control (squares) and 0.2% triton X-100 was utilized as positive control (triangles). Vertical bars correspond to standard deviation.
Bioassays
Aiming to investigate the antimicrobial activity of recombinant Pg-AMP1 a bacterial trial was performed to understand the ability of this peptide to inhibit microorganism proliferation. The recombinant Pg-AMP1 clearly exhibited antimicrobial activities with lower MICs against three Gram-positive bacteria tested (7.1 M). Otherwise, the deleterious activity against S. epidermides was higher than for the other pathogens evaluated, showing MIC of 100 g mL −1 . Moreover, the recombinant Pg-AMP1 showed antimicrobial activities against the four Gram-negative tested strains, with identical MICs of 100 g mL −1 (Table 1) , while control extracts did not show antibacterial activity. In order to evaluate the Pg-AMP1 hemolytic activity, the peptide was assayed in the presence of RBCs at concentrations of 200, 100 and 50 g mL −1 . Pg-AMP1 was able to lyses RBCs only at higher concentration (200 g mL −1 ). Otherwise, no significant hemolysis was obtained at lower concentrations (Fig. 3) .
Molecular modeling
Since we observed a modified activity of heterologous Pg-AMP1 in comparison to natural one, structural models were constructed to elucidate this functional variation. The first structure yielded by QUARK was composed of one N-terminal ␣-helix, starting from Pro 5 until Arg 17 for both sequences. The subsequent residues had no well-defined structure (data not shown). These first structures are in agreement with PsiPred secondary structure prediction, indicating an ␣-helix (residues 9-19) and a random coil in the remaining residues for both sequences. PrDOS indicates that structures are mostly disordered. There are two chaotic regions in the structures, the first at the N-terminal and the second starting from residue Tyr 41 until C-terminal residue (Fig. 4) . The other disordered region is entailed due to the presence of several short side chain residues such as glycine and serine, providing structural flexibility, and there are two prolines near the C-terminal that also contribute protein structure disorder. Proline residues lack an amide proton, essential to stabilize a secondary structure, and proline residues influence the preceding residue, favoring extended conformations [16, 35] .
Therefore, given the structural flexibility, Modeller's looprefinement sub-routine was used in order to build novel structures. It was applied on residues ranging from Tyr 17 to Arg 56 for natural Pg-AMP1; and from Tyr 18 to His 62 for recombinant Pg-AMP1. The ten best models for Pg-AMP1 show a DOPE score ranging from −1652.65503 to −1530.26282; for recombinant Pg-AMP1, −2335.47974 to −1945.35217. PROCHECK and ProSA analysis shows that the generated structures are in agreement with dihedral angles of known structures. For Pg-AMP1, Ramachandran plot shows 91.7% of residues in favored (77.8%) plus allowed regions (13.9%) for the worst model and 100% of residues in favored (94.4%) plus allowed regions (5.6%) for the best one. For recombinant Pg-AMP1, it shows 90.7% in favored (72.1%) plus allowed regions (18.6%) for the worst model and 100% of residues in favored (88.4%) plus allowed regions (11.6%) for the best one. The overall G-factors vary from −2.86 to −1.48 for Pg-AMP1 models; for recombinant Pg-AMP1 models they vary from −0.19 to −0.07, which indicates that the models are ordinary structures. Z-scores on ProSA indicate that the structures have similar quality to that solved by magnetic nuclear resonance. They vary from −3.36 to −1.47 for Pg-AMP1 and −3.9 to −2.16 for recombinant Pg-AMP1. The refined structures have the same overall fold of the first structure yielded by QUARK, one ␣-helix, ranging from Pro 4 to Tyr 19 , and a random coil (Fig. 4) ; some structures from recombinant Pg-AMP1 show an ␣-helix that is one or two residues longer at N-termini than Pg-AMP1. These data suggest that both Pg-AMP1 and its recombinant form can assume several conformations, which may have a great importance in its activity.
Discussion
Several AMPs have being described as antibacterial and antifungal, generally promoting pathogen membrane disruption or affecting DNA, RNA and\or protein synthesis and regulation pathways [9, 16] . Nevertheless, different bacterial resistance mechanisms have being observed including modification on membrane surface charges, membrane proteins composition or proteolytic enzymes secretion [2] . Perron et al. [29] related the resistance development to pexiganan (an analog of magainin I) in E. coli and Pseudomonas fluorescens after 600-700 generations of exposition to this peptide. By this way, Peschel and Sahl [30] suggested that resistance to cationic peptides may co-evolve with the pathogen. In spite of the presence of AMPs mechanisms of resistance, these compounds have emerged as promising candidates for antibiotics development [11] . Some products using AMPs have been developed by the pharmaceutical industry's such as Mx-226, which is used as a topical antibiotic for the prevention of catheter-related infections and the pexigan, that makes part of a topical cream utilized for diabetics foot ulcers treatment [9] .
Among the AMPs, the GRPs have also shown potent antimicrobial activities. The antimicrobial peptide Pg-AMP1, a glycine-rich AMP from Psidium guajava that has 14 identified glycine residues (22.5%) (Fig. 1) , was purified for the first time by Pelegrini et al. [28] , showing clear antibacterial activity. The GRPs identified from the mud crab Scylla paramamosain also exhibited antimicrobial activity against Gram-positive bacteria [12] . Nevertheless, other functions have also been assigned to GRPs. Glycine-rich peptides isolated from Avena sativa and Ginkgo biloba showed a chitin binding domain that provides inhibitory properties against filamentous fungi [4] . Moreover, the insect GRP tenecin-3 was able to control Candida albicans cells [9] and SK84 from Drosophila virilis showed antimicrobial and anti-cancer cell activities [23] .
The native Pg-AMP1 showed potent antimicrobial activities but its production from guava seeds was insufficient for biopharmaceutical production [28] . This fact is extremely common when native plants are involved, showing peptide expression elicited by environment changes, seasonality and other environmental uncontrolled factors. In order to overcome such problems, synthetic or recombinant peptides are excellent biotechnological alternatives [16] .
In the present work the recombinant Pg-AMP1 was first fused to a single histidine tag to reduce the costs and time for isolation. His6 tag protein may cause proteolysis protection, solubility and generally does not affect protein folding [21] . Moreover, small amounts of inclusion bodies were observed during Pg-AMP1 expression, probably produced by insoluble protein (data not shown). Generally, eukaryotic small proteins such as interleukins and insulin, when expressed in a prokaryotic system, may form similar aggregates [17] . The main cause of incorrect protein folding seem to be the low number of chaperone molecules that results in the formation of inclusion bodies [21] .
The recombinant Pg-AMP1 showed different activity from the native form, including activity against Gram-positive S. aureus (Table 1 ). These data suggest that addition of some amino acid residues for cloning and expression may alter the main function of Pg-AMP1. Some authors proposed that the histidine tag may alter secondary conformation and its biological activity [14] . Furthermore, hemolytic assays showed RBCs lysis only at higher Pg-AMP concentrations suggesting that peptide shows higher affinity to prokaryotic cell membranes. This specificity may occurs due to a reduced quantity of negatively charged lipids and also the cholesterol presence on human cells [44] .
The molecular models show that the histidine tag does not generate clear structural modifications (Fig. 4) . The GRPs are characterized by glycine repeat domains, which confer them high flexibility and may act as Velcro type during protein-lipid interactions [24] . According to Sachetto-Martins [32] (Fig. 1) . Glycine repetitions in the sequence provide structural flexibility as previously described [28] , allowing it to assume diverse loop conformations like those observed in molecular modeling (Fig. 4) . In this case the utilization of several structures is particularly important for a better characterization of its alternative conformations. Through the molecular modeling method employed in this study, several answers could be reaching about Pg-AMP1 structures. In fact, there are several possible conformations for Pg-AMP1, without a tendency to a specific fold type. In contrast to a previous report [28] , the molecular model of Pg-AMP1 here reported shows only the N-termini ␣-helix, indicating that the probable structure could be more flexible than previously described.
The same scenario was assumed for the recombinant Pg-AMP1 structural prediction, in which extremely flexible structures were observed. Carson et al. [3] showed that the His6 tag normally does not alter the structure of recombinant proteins. In our predictions, the His6 tag takes on a random coil conformation, as well as the C-terminal of predicted Pg-AMP1structure. Otherwise, despite the overall structure maintenance, the His6 tag seems to alter the Pg-AMP1 activity, since the recombinant protein is active against bacteria in which the native form is completely inactive, such as Gram-positive bacteria S. aureus and S. epidermides. These data indicate that the His6 tag may alter the mechanism of action of Pg-AMP1. The His6 tag probably increases the affinity of recombinant Pg-AMP1 to bacterial membranes, providing an stronger interaction with anionic membranes, due to the increase in positive C-terminal charges. The net charge seems to be an essential property to antimicrobial activity. Dathe et al. [5] had conducted an study generating several analogs of magainin. The analogs were designed for keeping several properties such as hydrophobicity and helix propensity, changing only the net charge. The more active analogs were the ones with charges higher than +5. In this view, the His6 tag could generate a similar effect to observed in the magainin analogs developed by Dathe et al. [5] . Bearing this in mind, we propose that the N-terminal is responsible for membrane binding, independently of the helix being one or two residues longer as observed in some models of recombinant Pg-AMP1, acting as a membrane anchor mediated by the three arginine residues. Subsequently, the random coil starts to interact with phospholipids, destabilizing the membrane. Metaphorically, this peptide would acts like a chain whip, an Asian melee weapon. The recombinant protein would be a chain whip with a sharper metal dart, the His6 tag (Fig. 4) .
In conclusion, it was observed that heterologous expression of Pg-AMP1 conserved its antimicrobial activity, enabling this peptide to be a candidate for production of antimicrobial compounds. Moreover, theoretical modeling clearly shows that the proposed structure is extremely variable due to flexibility of high glycine content. The presence of the His6 tag seems to not show clear structural modifications according theoretical studies here proposed and probably caused smooth antimicrobial activities modifications. In summary peptide engineering could help, in a near future, to find the essential Pg-AMP1 regions involved on antimicrobial activity. Once that this regions have being found, it will be possible to enhance the bactericidal activity by switching amino acid residues and also reduce the costs by reducing Pg-AMP1 length, leading to a possible application on industrial drug development.
